The anti-AIDS drug rilpivirine undergoes conformational changes to bind HIV-1 reverse
The anti-AIDS drug rilpivirine undergoes conformational changes to bind HIV-1 reverse transcriptase and retain potency against drug-resistance mutations. a pocket from the p66 subdomain where drug-resistance mutations happen.1,2 The NNRTI rilpivirine (TMC278/Edurant), a powerful diarylpyrimidine (DAPY) inhibitor of wild-type (WT) and NNRTI-resistant viruses, recently received FDA approval as an anti-AIDS medication. Previous studies show that … [Read more…]